← Back to the Areas of Interest
Pfizer Oncology - Building a new paradigm in prostate cancer
Astellas - Improving advanced prostate cancer patients’ lives with early treatment intensification
AstraZeneca - PARP inhibitors in the treatment of metastatic castrate resistant prostate cancer
Advanced Accelerator Applications, a Novartis Company - Elucidate metastatic prostate cancer targets with radioligand therapy and molecular profiling: Advancing precision medicine in prostate cancer
View the full invitation
F. Hoffmann-La Roche Ltd. - Reshaping treatment paradigms for GU cancer patients: Perspectives on PI3K/AKT inhibitors in mCRPC and immunotherapy in urothelial cancer
Programme and Faculty are preliminary and subject to change.
© 2019 cSLIDE CTI MEETING TECHNOLOGY. All rights reserved.